Calcium channel

Tardive Dyskinesia (TD) Treatment Drugs Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 12, 2022
Health, Pharmaceutical, FDA, Calcium channel, L-DOPA, Reserpine, Tardive dyskinesia, Amantadine, GCC, Prevalence, Benzodiazepine, TD, Neurological disorder, Vitamin E, Pharmaceutical industry, Bottled water

The "Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The report includes in-depth analysis of TD treatment drugs market for period from 2020 to 2029.
  • Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.
  • Based on drug types, the global tardive dyskinesia (TD) treatment drugs market is segmented as follows:
    For the purpose of this study, the global tardive dyskinesia (TD) treatment drugs market is categorized into:

The Abdominal Aortic Aneurysm Market to Boost at a CAGR of 3% During the Study Period (2019-32), Assesses DelveInsight

Retrieved on: 
Monday, May 2, 2022
Aortic rupture, United Kingdom, Stomach, Population, Blood pressure, Abdominal aortic aneurysm, LAS, C1-inhibitor, Aorta, Abdomen, Prevalence, Aneurysm, Patient, Bifurcation, Magnetic resonance angiography, Calcium channel, Cook Group, CT, Human, Incidence, Pressure, Medtronic, Cardinal Health, Anatomy, Spine, Disease, And, AAA, Technology, Growth, Sensation, Tobacco, Shenzhen, Risk, Medical imaging, Cultured pearl, Dairy product

LAS VEGAS, May 2, 2022 /PRNewswire/ -- DelveInsight's Abdominal Aortic Aneurysm Market Insights report includes a comprehensive understanding of current treatment practices, Abdominal Aortic Aneurysm emerging treatment devices, market share of therapy classes, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Points: 
  • The majority of Abdominal Aortic Aneurysm grow slowly without noticeable Abdominal Aortic Aneurysm symptoms.
  • The Abdominal aortic aneurysm ultrasound and Abdominal aortic aneurysm CT scan are among the most commonly used tools for Abdominal aortic aneurysm diagnosis.
  • The Abdominal Aortic Aneurysm Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
    There are currently no Abdominal Aortic Aneurysm drugs available to slow the growth of Abdominal Aortic Aneurysm.
  • Moreover, the growing geriatric population and Abdominal Aortic Aneurysm incidence in Western countries present a profitable opportunity for the Abdominal Aortic Aneurysm market.

Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day

Retrieved on: 
Wednesday, April 27, 2022
Drug development, Calcium channel, Judgement, IND, Media, U.S. Securities and Exchange Commission, COVID-19, Twitter, Genetics, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, SYNGAP1, SCN2A, Security (finance), Annual report, Epilepsy, Food, Private Securities Litigation Reform Act, CNS, Central nervous system, Brain, GLOBE, Lists of diseases, Patient, Goal, LinkedIn, ASO, Review, Event, Trial of the century, Update, Drug discovery, Tuberous sclerosis, Webcast, Investor, Movement disorders, SCN8A, Central nervous system disease, FDA, TSC, Pharmaceutical industry, Praxis

We have made considerable progress enabling a high-value portfolio across each of our three franchises, and we look forward to sharing our continued progress across the entire Praxis pipeline.

Key Points: 
  • We have made considerable progress enabling a high-value portfolio across each of our three franchises, and we look forward to sharing our continued progress across the entire Praxis pipeline.
  • A replay of the webcast will be available on Praxis website for 90 days following the event.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
  • Praxis has established a broad portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders, epilepsy and other exploratory CNS indications, with three clinical-stage product candidates.

Fresenius Kabi Introduces Calcium Gluconate in Sodium Chloride Injection in Ready-to-Administer freeflex® Bags

Retrieved on: 
Wednesday, April 27, 2022
General Health, Other Health, Hospitals, Health, Pharmaceutical, ECG, Arrhythmia, CEO, Calcium, Infection, Ceftriaxone, Vitamin D, Kidney failure, LLC, Glycosidic bond, Adult, Aluminium, Vasodilation, Syncope, Calcium channel, Calcium gluconate, Hypercalcaemia, Â, Patient, Necrosis, Inflammation, Sodium chloride, Safety, Plasma, Fresenius (company), Ulcer, Calcinosis cutis, Hypotension, Vitamin A, Cardiac arrest, Blood vessel, Multimedia, FDA, Calcification, Hypocalcemia, Pharmaceutical industry, Salt, Medical device, Phosphorus, Calcinosis, Bradycardia

Fresenius Kabi announced today it has introduced two new presentations of Calcium Gluconate in Sodium Chloride Injection in the United States in the companys proprietary, ready-to-administer freeflex containers.

Key Points: 
  • Fresenius Kabi announced today it has introduced two new presentations of Calcium Gluconate in Sodium Chloride Injection in the United States in the companys proprietary, ready-to-administer freeflex containers.
  • By offering Calcium Gluconate Injection in two delivery systems, Fresenius Kabi can provide health care professionals with more flexibility and choice to best serve patient needs.
  • Calcium Gluconate in Sodium Chloride Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia.
  • Calcium Gluconate in Sodium Chloride Injection is contraindicated in hypercalcemia and in neonates (28 days of age or younger) receiving ceftriaxone.

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT

Retrieved on: 
Thursday, April 14, 2022
Annual report, Pain, U.S. Securities and Exchange Commission, Conference call, COVID-19, Atrial fibrillation, MBA, Twitter, Anxiety, Private Securities Litigation Reform Act, Lightheadedness, RAPID, News, Risk, Patient, Paroxysmal attack, Duke University School of Medicine, Form 10-K, Paroxysmal supraventricular tachycardia, Syncope, Conference, Review, FHRS, KOL, Company, Nasdaq, Dizziness, Webcast, Forward-looking statement, Perspiration, GA, Research, Safety, Education, Adenosine, Calcium channel, Assistant, Revera, Pandemic, Palpitations, Fatigue, PSVT, Pharmaceutical industry, MD, Milestone

ET

Key Points: 
  • ET
    MONTREALandCHARLOTTE, N.C., April 14, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc.(Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m.
  • The event will focus on etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT).
  • Certain intravenous medications, including adenosine, beta-blockers and calcium channel blockers, have long been used for the acute treatment of PSVT.
  • Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.

Assessment of the Global Market for CNS Therapeutics, 2022 - US Market is Projected to Reach $70 Billion by 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Other Manufacturing, Manufacturing, Therapy, CAGR, Population, GABA, Seizure, Parkinson, Calcium channel, AMPA, Beta blocker, Fibrin, Neurodegeneration, Growth, Compliance, CNS, Lists of diseases, Incidence, Prescription, Tissue, Adenosine, Schizophrenia, Quality of life, Injury, Alzheimer's disease, Industry, Hyaluronic acid, Stroke, Memory, Ageing, COVID-19, B cell, Life expectancy, US, Sleep, Attention, Anxiety, Awareness, Central nervous system disease, Depression, Degenerative disease, Collagen, Pharmaceutical industry, Neuro

Amid the COVID-19 crisis, the global market for CNS Therapeutics is projected to reach US$132.1 Billion by 2024, registering a compounded annual growth rate (CAGR) of 5.1% over the analysis period.

Key Points: 
  • Amid the COVID-19 crisis, the global market for CNS Therapeutics is projected to reach US$132.1 Billion by 2024, registering a compounded annual growth rate (CAGR) of 5.1% over the analysis period.
  • The United States represents the largest regional market for CNS Therapeutics, accounting for an estimated 50.2% share of the global total.
  • The market is projected to reach US$70 Billion by the end of the analysis period.
  • The market is on a growth trajectory led by increasing incidence of CNS diseases, rapidly growing aging population, and rising healthcare expenditure.

Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562

Retrieved on: 
Tuesday, January 18, 2022
American Epilepsy Society, Patient, Autonomic, Epilepsy, Seizure, AED, Central nervous system, LinkedIn, Conjunctiva, ASSR, Private Securities Litigation Reform Act, European Medicines Agency, CNS, COVID-19, Central nervous system disease, Movement disorders, Adult, NASDAQ, NAV, Gene, GLOBE, Sodium, Review, Calcium channel, Physiology, Trigeminal neuralgia, Development of the human body, U.S. Securities and Exchange Commission, Goal, SUNA, Company, Disorder, Depression, Pathology, Food, Lists of diseases, Twitter, Brain, Security (finance), SUNCT, Food and Drug Administration Amendments Act of 2007, Dees, Judgement, Annual report, Pharmaceutical industry, Praxis

BOSTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the publication of data in the journal Epilepsia from a preclinical study of PRAX-562, a preferential persistent sodium channel blocker currently in development for the potential treatment of rare adult cephalgias and Developmental and Epileptic Encephalopathies (DEEs).

Key Points: 
  • This preclinical study investigated the effects of PRAX-562 on intrinsic neuronal excitability and protection from induced seizures as compared to sodium channel blockers used as standard-of-care antiepileptic treatments.
  • In the study, PRAX-562 demonstrated robust preclinical antiseizure activity and significantly improved preclinical tolerability, with improved or comparable efficacy when evaluated against currently used sodium channel blockers.
  • This study supports the potential for PRAX-562, a persistent sodium channel blocker with a favorable therapeutic window, to improve tolerability relative to marketed therapies while achieving potent antiseizure activity.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Nocion Therapeutics Announces Dosing Underway in Participants with Chronic Cough

Retrieved on: 
Tuesday, August 31, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Pharmacology, University, Nociceptor, Health care, Pain, Medicines and Healthcare products Regulatory Agency, CSCB, Respiratory Medicine, LPC, Chronic cough, Anxiety, NHS foundation trust, Doctor of Philosophy, Therapy, Manchester University NHS Foundation Trust, Mark (given name), University of Manchester, Neuron, Cough, Calcium channel, Bachelor of Medicine, Bachelor of Surgery, Itch, Safety, Adult, Medical device, Sodium, Patient, Depression, FRCP, MHRA, COVID-19, Medication, Part, Pharmaceutical industry

Nocions first-in-class proprietary molecule is being developed as a treatment for cough indications including Chronic Cough.

Key Points: 
  • Nocions first-in-class proprietary molecule is being developed as a treatment for cough indications including Chronic Cough.
  • The ongoing Phase 2a trial is a two-part study being conducted first in participants with Chronic Cough and then in participants with Acute Cough, including postinfectious cough following COVID-19.
  • Chronic Cough is cough lasting more than eight weeks and is associated with significant, debilitating physical, social and psychosocial impact.
  • This broad mechanism has shown significant antitussive effects in preclinical models of cough, superior to that of P2X3 antagonists, and forms the basis for its use in cough indications beyond Chronic Cough.